CORRECTED-GTx says muscle drug fails in late-stage trials
(Corrects the number of patients to "about 650" from "about 325")
Aug 19 (Reuters) - GTx Inc said its experimental drug to treat muscle wasting in cancer patients was not effective in improving body mass in late-stage trials.
A 3-mg dose of the drug, enobosarm, was tested on about 650 patients with non-small cell lung cancer - the most common form of lung cancer.
There is no approved cure for cancer-induced muscle wasting which causes decreased physical function, fatigue and weight loss. (Reporting by Pallavi Ail in Bangalore; Editing by Saumyadeb Chakrabarty)
- Putin dissolves state news agency, tightens grip on Russia media
- North Korea says Kim's powerful uncle dismissed for 'criminal acts'
- Thai PM calls snap election, protesters want power now |
- Record cold, ice grip U.S.; more snow to blanket East
- Protesters fell Lenin statue, tell Ukraine's president 'you're next'